Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Phuong H. Dao"'
Autor:
Michael J. Buege, Esther Drill, Steven M. Horwitz, Andréa LeVoir, Terry Pak, Tim J. Peterson, Phuong H. Dao, Matthew J. Matasar
Publikováno v:
European Journal of Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ba72d1fec5ac58a2cb0847399c94d38
https://doi.org/10.1111/ejh.13971
https://doi.org/10.1111/ejh.13971
Autor:
Anas Younes, Joy C. Jarrett, Anita Kumar, Tara A. Duggan, Alison J. Moskowitz, Megan H. Leary, Ariela Noy, Colette Owens, Lorenzo Falchi, Gottfried von Keudell, Michael J Buege, Brianne N. Dixon, Paul A. Hamlin, Phuong H. Dao, Matthew J. Matasar, Andrew D. Zelenetz, Terry K. Pak, Philip Caron, Audrey Hamilton
Publikováno v:
Leukemia & Lymphoma. 63:876-884
R ± DHAX has been traditionally administered to inpatient due to the timing of chemotherapy administration and the perceived need for close monitoring of adverse effects. To administer R ± DHAX outpatient, a multidisciplinary task force created cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::062d99fd8e510e5ea8cf510f2d562eb4
https://doi.org/10.1080/10428194.2021.2002318
https://doi.org/10.1080/10428194.2021.2002318
Autor:
Andréa LeVoir, David J. Straus, Tim J Peterson, Terry Pak, Michael J Buege, Phuong H. Dao, Esther Drill
Publikováno v:
Clin Lymphoma Myeloma Leuk
IVAC +/− rituximab (R) is used as standalone therapy in relapsed/refractory non-Hodgkin lymphomas (NHL) despite a paucity of data. We report a retrospective cohort of 54 patients with relapsed/refractory NHL treated with IVAC +/− R. Objective res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8c87311be047c50c743938cce44d7a
https://europepmc.org/articles/PMC8643303/
https://europepmc.org/articles/PMC8643303/
Autor:
Tim J Peterson, Phuong H. Dao, Steve Horwitz, Andréa LeVoir, Michael J Buege, M. Matasar, Esther Drill, Terry Pak
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5ec70718f4170a737c5391b506b1ff0
https://doi.org/10.1002/hon.193_2880
https://doi.org/10.1002/hon.193_2880
Autor:
Krisoula Spatz, Prakirthi Yerram, Lauren DeRespiris, Richard F Tizon, Terry K. Pak, Andréa LeVoir, Scott Freeswick, Samantha N Reiss, Lisa Modelevsky, Josiah D. Land, Sherry Mathew, Carmen Lau, Shirley Qiong Yan, Lauren Koranteng, Phuong H. Dao, Kate E Reichert, Jennifer Thackray, Nicole P Daukshus, Jennifer S. Orozco, Stephen Harnicar, Larry W Buie, Manpreet K. Boparai, Michael J Buege, Dazhi Liu
Publikováno v:
J Oncol Pharm Pract
PurposeWith the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide direct clinical care safely to cancer patients. Allocating the workforce was necessary to m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2232d99ac821194bf5e6eebc3d4856
https://pubmed.ncbi.nlm.nih.gov/33459159
https://pubmed.ncbi.nlm.nih.gov/33459159
Autor:
Terry Pak, Andréa LeVoir, Tim J Peterson, Esther Drill, Phuong H. Dao, Michael J Buege, David J. Straus
Publikováno v:
Blood. 136:10-10
Introduction Part B of the modified Magrath regimen (ifosfamide, etoposide, and cytarabine; IVAC) with or without rituximab (R) is utilized as a standalone regimen in the management of relapsed/refractory Burkitt lymphoma and other non-Hodgkin lympho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aee9919048e7696d20b319824d60c4e7
https://doi.org/10.1182/blood-2020-134607
https://doi.org/10.1182/blood-2020-134607